<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-KYQQTGWH/08a52892-59b7-40b8-9da3-6a9b38f289d8/PDF"><dcterms:extent>376 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-KYQQTGWH/fb7b9cdf-b7e0-44d4-b520-0dc41b3b93fb/TEXT"><dcterms:extent>64 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-KYQQTGWH"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2015</dcterms:issued><dc:creator>Černe, Katarina</dc:creator><dc:creator>Ferjan, Ilonka</dc:creator><dc:creator>Kržan, Mojca</dc:creator><dc:creator>Lipnik-Štangelj, Metoda</dc:creator><dc:creator>Stanovnik, Lovro</dc:creator><dc:creator>Žiberna, Lovro</dc:creator><dc:format xml:lang="sl">številka:6</dc:format><dc:format xml:lang="sl">letnik:84</dc:format><dc:format xml:lang="sl">str. 456-471</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:32064217</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-KYQQTGWH</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">cannabis</dc:subject><dc:subject xml:lang="en">drug</dc:subject><dc:subject xml:lang="en">endocannabinoids</dc:subject><dc:subject xml:lang="sl">endokanabinoidi</dc:subject><dc:subject xml:lang="en">function</dc:subject><dc:subject xml:lang="sl">funkcija</dc:subject><dc:subject xml:lang="sl">konoplja</dc:subject><dc:subject xml:lang="en">legal status</dc:subject><dc:subject xml:lang="sl">legalni status</dc:subject><dc:subject xml:lang="en">preparations</dc:subject><dc:subject xml:lang="sl">receptorji</dc:subject><dc:subject xml:lang="en">receptors</dc:subject><dc:subject xml:lang="sl">toksičnost</dc:subject><dc:subject xml:lang="en">toxicity</dc:subject><dc:subject xml:lang="sl">zdravila</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Farmakologija kanabinoidov| Pharmacology of cannabinoids|</dc:title><dc:description xml:lang="sl">Background: In this article, a facial reconstruction with implant-supported craniofacial epitheses and our clinical experience with the substitution of auricular and orbital region are described. Materials and methods: In this case series, 9 patients with 28 endosseous implants performed in the period between 2006 and 2013 were included. Two-stage and one-stage procedures were opted for; the former in six patients, and the latter in three patients. There were four patients with congenital defects of facial structures, and five patients who had undergone ablative oncological surgery; three among them received postoperative radiotherapy. In two patients adjuvant therapy with hyperbaric oxygen was used before and after implantation. We analysed the success of combined surgical-prosthodontic treatment. Results: We placed 28 titanium implants in 9 patients. A successful osseointegration was observed in 27 implants; only one endosseous implant failed to integrate and fell out of the bone (in an irradiated patient). The final implantsupported epithesis was achieved in six patients. Among them there were five ear-substituting epitheses and one epithesis substituting the eye and periorbital region. The final epithesis could not be made in three patients; in one patient too much keloid formed to fix a prosthodontic bar to the implants, the other two patients died because of the progression of malignancy. Conclusion: The surgical technique for rehabilitation using implant-supported facial epitheses is simple and reliable. In certain indications, it is the only proper option for aesthetic and socially acceptable rehabilitation. The major problem remains soft tissues surrounding the implants. Due to their stability and appearance, the implantsupported epitheses are superior to the adhesiveretained epitheses</dc:description><dc:description xml:lang="sl">Odkritje receptorjev za derivate iz konoplje in endokanabinoidnega sistema je privedlo do številnih možnosti za terapevtsko uporabo kanabinoidov. V osrednjem živčevju kanabinoidi učinkujejo predvsem modulatorno, uravnavajo sproščanje drugih nevrotransmitorjev prek aktivacije receptorjev CB1. Aktivacija receptorjev CB2 zunaj osrednjega živčevja povzroča zmanjšanje vnetnega odgovora in povečanje apoptoze nekaterih tumorskih celic. S kanabinoidi lahko zdravimo slabost in bruhanje, izzvano s citostatiki; stimuliramo apetit; blažimo nevropatsko bolečino in spastičnost pri multipli sklerozi ter bolečino pri bolnikih z rakom. Učinkovitost pri drugih boleznih in stanjih se še preverja. Izolacija in identifikacija posameznih kanabinoidov iz konoplje in sinteza bolj selektivnih derivatov povečuje terapevtske možnosti. Ob tem se pojavljajo številni problemi z neželenimi učinki, zlasti, kadar gre za uporabo pripravkov iz konoplje z neznano količinsko in kakovostno sestavo. Med toksičnimi učinki kanabinoidov so najbolj zaskrbljujoči kronični učinki, kot so odvisnost, toleranca z odtegnitvenimi simptomi, povečano tveganje za ponovni akutni miokardni infarkt in povečano tveganje za razvoj psihoz oziroma poslabšanje simptomov pri že obstoječi psihozi. Akutni učinki so bolj izraženi pri otrocih, pri katerih je bila pri naključnem zaužitju opažena huda depresija osrednjega živčevja. Za potencialna zdravila iz konoplje in sintetične kanabinoide morajo veljati enaka pravila kot za druga potencialna zdravila. Tudi če je snov naravnega (rastlinskega) izvora in ima biološke učinke, moramo uporabnost za zdravljenje in sprejemljivo varnost za bolnika dokazati v nekliničnih preizkušanjih in kliničnih študijah, dovoljenje za promet pa mora izdati ustrezen organ. Bolniki pa si zaslužijo tudi kakovostno izdelana zdravila, ki vedno vsebujejo predpisano količino t. i. "remedii cardinalis"</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-KYQQTGWH"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-KYQQTGWH" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-KYQQTGWH/08a52892-59b7-40b8-9da3-6a9b38f289d8/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-KYQQTGWH/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-KYQQTGWH" /></ore:Aggregation></rdf:RDF>